Цитрапар

Quick links

Choose a section

Quick links to important sections

Advertisements

Цитрапар

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Цитрапар

This section provides a brief overview of the identity, composition, and general purpose of the combination medicine, Цитрапар.

Quick Facts Description
Active Ingredients Paracetamol, Acetylsalicylic acid (ASA), and Caffeine
Form Oral Tablets
Pharmacological Class Analgesic-Antipyretic Combination
Common Use Principle Pain Relief and Fever Reduction
Origin Synthetic

The Essence of Цитрапар: Identity and Class

Цитрапар is a synthetic, three-component pharmaceutical product known as an analgesic-antipyretic combination medicine, taken orally in tablet form. This classification highlights its dual function—it is intended both to relieve pain and to reduce fever. Unlike medications containing only a single active compound, its identity rests on the synergistic blend of three components, designed to enhance overall efficacy. The inclusion of caffeine is intended to enhance the effect of the primary pain relievers in such combination products, leading to faster relief. This means the medicine is scientifically designed to start working more efficiently than if the ingredients were taken separately. Цитрапар is one of several widely used generic combinations containing these three ingredients, often functioning as an Over-the-Counter (OTC) option for general discomfort.


Composition and General Purpose

The drug is composed of Paracetamol, Acetylsalicylic acid (ASA), and Caffeine. The principle behind this composition is synergy: utilizing different pharmacological mechanisms to provide comprehensive relief. Paracetamol targets pain and fever centrally, while ASA (an NSAID) provides anti-inflammatory and peripheral analgesic action. Caffeine serves as an adjuvant, boosting the performance of the other two ingredients. This combination strategy is well-established, utilizing ingredients for treating common discomforts like headache and fever. Simply put, this multi-ingredient approach is recognized for its ability to tackle pain from different angles, making it a highly efficient solution for acute symptoms. The formulation is specifically popular for its fast-acting profile and is positioned as a go-to relief option for transient, mild-to-moderate symptoms.

Advertisements

What side effects are possible with Цитрапар?

Possible Side Effects and Safety Information

Regulatory authorities classify the safety profile of Цитрапар (Ziprasidone) by the severity and system-organ class of documented adverse reactions. The most serious and clinically significant risks include an Increased Risk of Death in Elderly Patients with Dementia-Related Psychosis, which is subject to a formal Boxed Warning.

Serious and Clinically Significant Adverse Reactions

The medicine is associated with several potentially fatal or irreversible events. These include Neuroleptic Malignant Syndrome (NMS), a serious condition involving high fever and muscle rigidity, and Severe Cutaneous Adverse Reactions (SCAR), such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Risk of Tardive Dyskinesia, involving involuntary, uncontrollable movements, is also documented. Cardiovascular risks include QT interval prolongation, which can lead to Torsades de Pointes and sudden cardiac death, leading to contraindications in patients with certain pre-existing heart conditions or those using other QT-prolonging drugs.

Common Adverse Reactions and Monitoring

Adverse reactions that occur commonly include somnolence (drowsiness), dizziness, nausea, and extrapyramidal symptoms (involuntary movement disorders).

The safety profile also includes the risk of metabolic changes, such as hyperglycemia (high blood sugar/diabetes), dyslipidemia, and weight gain. Official guidance requires monitoring of these metabolic parameters, along with potential changes in complete blood counts due to the risk of leukopenia or neutropenia.

Population and Usage Restrictions

Цитрапар is contraindicated for use in elderly patients with dementia-related psychosis due to the increased mortality risk. Use during the third trimester of pregnancy has been associated with a risk of extrapyramidal or withdrawal symptoms in the newborn.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of this combination product presents as a Multi-Component Toxidrome, reflecting the acute toxicities of Acetaminophen, Acetylsalicylic acid (ASA), and Caffeine. The most critical risk is severe liver damage and liver failure linked to the Acetaminophen component, which may not show early symptoms. Salicylate toxicity (Salicylism) is characterized by signs such as tinnitus (ringing in the ears), headache, fever, confusion, and complex metabolic disturbances like metabolic acidosis.

Immediate symptoms may include nausea, vomiting, sweating, agitation, and palpitations (rapid heart rate). Severe outcomes, as documented in official prescribing information, include coma, seizures, and gastrointestinal hemorrhage. Risk of severe hepatic injury is increased in patients with hepatic impairment, severe renal impairment, or chronic alcoholism.

Emergency-Response Statements

Action Required Condition Source Alignment
Seek immediate medical help Any suspected overdose, regardless of current symptoms Government regulatory labels
Call emergency services (e.g., 911) Victim has collapsed, had a seizure, or has trouble breathing Official emergency instructions

Prompt medical attention is critical for adults and children even if the victim feels well, due to the delayed onset of severe toxicity. Acetylcysteine is the specific antidote used for the Acetaminophen component. Monitoring in a clinical setting involves checking liver enzymes and serum acetaminophen concentration.

Advertisements

Therapeutic Uses of Цитрапар

What Цитрапар treats: main uses and benefits

The combination of Acetaminophen, Aspirin (ASA), and Caffeine is an analgesic-antipyretic formulation used for the symptomatic management of various acute discomforts. The therapeutic value of this combination lies in providing comprehensive, supportive relief and serves as part of the symptomatic management for symptoms related to pain and fever.

The application of this combination is relevant for addressing acute primary headaches. It provides supportive symptomatic relief across key domains, primarily addressing symptoms related to headache syndromes, systemic body aches, and elevated body temperature.

Key Symptom Domains

Цитрапар is used for the supportive therapeutic management of conditions characterized by episodic or fluctuating symptom patterns. This includes migraine headaches, tension-type headaches, generalized muscle aches, minor joint pain, and menstrual cramps. It is applied during phases when symptoms become more noticeable, offering supportive relief when symptoms create physiological strain. The use of this combination preparation supports general well-being during symptomatic phases when pain and fever become more pronounced.

"The combination is relevant in contexts involving heightened systemic burden, supporting the patient during difficult episodes by easing distress."

Quick Fact: Relief for Acute Discomfort
Primary Target Mild-to-moderate pain and fever
Symptom Clusters Headaches, muscle aches, and pyrexia
Core Benefit Contributes to easing the overall symptom load

Regulatory References

  1. NIH StatPearls overview
Advertisements

Eligibility and Restrictions for Use

The official eligibility profile for Цитрапар is defined by regulatory guidelines for its three active components: Acetaminophen, Aspirin, and Caffeine. Standard eligibility is for adults and children 12 years of age and over who have no established contraindications.

Population Eligibility Status Criteria and Restriction
Contraindicated Individuals with a known allergy to any component (Aspirin, Acetaminophen, NSAIDs). Prohibited for women in the third trimester of pregnancy. Must not be used by children or teenagers who have, or are recovering from, viral illnesses (due to the risk of Reye’s syndrome).
Absolute Exclusion Patients with severe hepatic or renal impairment and those with a history of active peptic ulcer or gastrointestinal bleeding must not use this medicine. Use is also excluded when concurrently taking any other product containing acetaminophen.
Restricted Use Individuals under 12 years are restricted and require professional guidance. Caution is advised for those aged 60 and older and patients with pre-existing conditions such as asthma, high blood pressure, heart disease, or non-severe liver/kidney disease. Use is restricted for those taking blood thinners, steroids, or other NSAIDs.

The eligibility structure emphasizes that non-eligibility is mandatory for high-risk groups, including those with component hypersensitivity or compromised organ function, while other populations face conditional use restrictions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Цитрапар (Citalopram) has specific, documented interactions that are detailed in regulatory labeling. It is crucial to be aware of these combinations, which fall into two main categories: contraindicated and use-with-caution.

Contraindicated Combinations

Concomitant use with the following substances is strictly prohibited:

  • Monoamine Oxidase Inhibitors (MAOIs): Including non-selective and selective reversible MAOIs (e.g., Linezolid), due to the high risk of Serotonin Syndrome. A required washout period must be observed when switching between Citalopram and an MAOI.
  • Medicines that Prolong the QT Interval: Combining Citalopram with other agents known to prolong the QT interval (e.g., Pimozide, certain antiarrhythmics) is strictly contraindicated due to the risk of serious ventricular arrhythmias.

Clinically Significant Interactions

These combinations require caution, as they may modify exposure or increase safety risks:

  • Serotonergic Medicinal Products: Co-administration with other serotonergic drugs (e.g., Triptans) may increase the risk of Serotonin Syndrome.
  • Drugs Affecting Haemostasis: Use with oral anticoagulants, NSAIDs, or antiplatelet drugs may increase the risk of bleeding/hemorrhage.
  • Metabolic Inhibitors: Co-administration with strong inhibitors of the CYP2C19 or CYP2D6 enzymes may increase Citalopram's plasma concentration, potentially necessitating closer clinical review.
  • Alcohol and Herbal Products: Concomitant use of alcohol and herbal products like St. John's Wort may increase the risk of adverse effects and is not advised.
Advertisements

Mechanism of Action

How Цитрапар Works

Цитрапар (Citrapar), as a citrate-based agent, exerts its action through a sequential modification of the body's acid-base balance and targeted physicochemical changes in the urinary system. The mechanism begins with the metabolism of the citrate component, primarily in the liver, which generates bicarbonate ( HCO3^-). This introduction of an alkaline load into the systemic circulation modulates the acid-base regulatory system, affecting processes involving acid-base dysregulation in systemic pathways.

Subsequently, the increased HCO3^- and filtered citrate raise the pH of the renal filtrate, leading to urinary alkalinization. In parallel, citrate acts as a chelating agent, directly binding to calcium ions within the tubular fluid, thereby reducing the concentration of free calcium ions. The combined effects of elevated pH and chelation increase the solubility of weakly acidic compounds, specifically uric acid. This engages molecular mechanisms that modify early physicochemical steps in crystal formation, influencing the overall saturation index of urinary solutes.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Цитрапар is strictly designated for oral administration as a tablet. The administration procedure and dosing regimen are precisely defined in labeling to ensure standardized use.


Administration Feature Official Instruction
Route and Form Used strictly for oral administration as a tablet.
Standard Adult Dose The standard single dose is two tablets (equivalent to 500 mg Acetaminophen, 500 mg Aspirin, and 130 mg Caffeine).
Maximum Daily Limit Consumption should not exceed eight tablets within a 24-hour period.
Dosing Frequency Doses must be separated by a minimum interval of six hours, taken as needed.
Administration Method The tablet must be swallowed whole with a full glass of water. The medicine may be taken independently of meals.

The official protocol outlines key constraints that govern the duration and content of use. The medication is to be administered only to individuals 12 years of age and older, following the adult dosing schedule. Continuous administration for general pain relief must not exceed 10 consecutive days, and use for fever reduction is strictly limited to 3 consecutive days. Furthermore, the procedural instructions require patients to avoid concurrent use with any other prescription or nonprescription products containing acetaminophen. Users must also limit the intake of additional caffeine from other sources while on this regimen. For headache management, guidelines indicate that this product should not be used for 10 or more days per month.

Advertisements

Recent Clinical Evidence

Research Evidence Overview

The clinical evidence for the Acetylsalicylic acid (ASA), Paracetamol, and Caffeine combination focuses on its use during acute, episodic discomfort, primarily in adult populations.

Studies in Headache Syndromes

Research for acute migraine headache relies heavily on multiple Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies explored whether there were changes in outcomes related to physical discomfort and daily functioning. Studies monitored measured endpoints such as achieving a pain-free state or significant pain reduction at two hours post-dose. The combination was also studied for use during acute episodes of tension-type headaches (TTH) in single-dose RCTs, which examined patterns related to pain reduction and headache intensity.


General Acute Pain and Study Gaps

The combination was observed in research contexts involving other acute mild-to-moderate pain, such as post-surgical pain or menstrual cramps. The evidence for these non-headache uses often involves meta-analyses that explored the research question of combining caffeine with standard analgesics, measuring the overall degree of symptom reduction. While these studies contribute to the evidence landscape, the specific triple combination has fewer large-scale dedicated RCTs for each individual non-headache pain type.


Limitations and Uncertainties

The key clinical trials were generally focused on healthy adults, and research is limited to assessing single-episode changes. Follow-up durations were limited across the core evidence base, meaning that long-term effects and the consequences of frequent or prolonged use are not fully established. Data for certain groups, such as older adults or patients with specific comorbidities, remain insufficient.

Key Studies & References Aspirin/Caffeine/Acetaminophen (A.C.A.) for Headache Management (StatPearls)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Цитрапар (FAQ)

Q: How quickly should I expect to feel the effects of Цитрапар?

Clinical studies often measure significant pain reduction or a pain-free state within two hours post-dose, which indicates the timeframe during which the effects are observed. The formulation includes caffeine, which is recognized as an adjuvant that is associated with supporting the action of the pain-relieving components.


Q: What should I do if I miss a dose of Цитрапар? (non-dosing instruction)

Since this type of medicine is commonly used only when needed (PRN), it may not follow a regular schedule. If the medicine is taken regularly and a dose is missed, official information states that taking it as soon as it is remembered is one approach described in the labeling. If the time for the next scheduled dose is near, skipping the missed dose and returning to the regular dosing schedule is typically advised, as doubling up doses is generally not recommended.


Q: What is the typical duration of action for a single use of Цитрапар?

Official administration guidelines require that doses be separated by a minimum interval of six hours. This mandatory separation period is an indication of the interval required between doses, which relates to the duration of the effect as measured in clinical use.


Q: How can I tell if my side effect is serious or normal when taking Цитрапар?

Official regulatory warnings describe specific signs that signal serious adverse reactions and require immediate medical assistance. These include signs of severe allergic reactions like hives or difficulty breathing, or symptoms of stomach bleeding, such as vomiting blood or having bloody or black stools. The official product information provides a full description of these warnings.


Q: What does 'contraindication' mean in the context of Цитрапар?

According to the official product information, a contraindication is a specific medical situation or condition where the medicine must not be used because the risks significantly outweigh any possible benefit. Examples include having a known allergy to any component or being in the third trimester of pregnancy, as listed in regulatory documents.


Q: Is it normal to feel a tingling sensation after taking Цитрапар?

A tingling sensation is not listed as a common adverse reaction for this product. However, medical sources sometimes note this as a potential symptom related to more severe conditions, such as dangerously high potassium levels. Official guidance states that if this or other unusual symptoms occur, medical attention should be sought to address potential serious issues.


Q: How long after taking a dose of Цитрапар is it eliminated from the body?

The time it takes for a medicine to be eliminated is tracked by a measure called the half-life, which describes how quickly the medicine leaves the body. Official regulatory information indicates that the different active components are eliminated at varying rates, with the process typically taking several hours for most of the medicine to be cleared.


Q: Are there different strengths of Цитрапар available?

Yes, regulatory information confirms that products containing this three-component combination are available in several strengths. The product is commonly marketed in a standard strength, but regulatory information shows that other strengths of the component combination may also be authorized.


Q: Does Цитрапар contain any substances that are banned in sports?

One of the active ingredients in this medicine is Caffeine. Official sports regulatory bodies monitor the use of caffeine; however, it is generally permitted for use in competition up to a specific, high concentration threshold in the urine.

Advertisements

How should Цитрапар be stored and disposed of?

The storage and disposal of Цитрапар (Paracetamol, Acetylsalicylic acid, and Caffeine) must strictly follow the conditions defined in the regulatory labeling.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Protect from excess heat and moisture; do not store in the bathroom or where conditions fluctuate.
Container Keep the medication in the original container with the cap tightly closed to maintain product stability.
Child Safety The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Discard unused or expired medication in accordance with local regulations and through an authorized medicine take-back program. Regulatory authorities advise not flushing the product down the toilet. If a take-back program is unavailable, mix the medicine with an unpalatable substance (like dirt) and seal it in a bag before disposal with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цитрапар found in:

A-Z Index: